Date | Price Target | Rating | Analyst |
---|---|---|---|
9/19/2024 | $52.00 → $57.00 | Overweight → Neutral | JP Morgan |
6/7/2024 | $48.00 → $51.00 | Overweight → Neutral | Piper Sandler |
2/29/2024 | $54.00 | Outperform | TD Cowen |
7/24/2023 | $61.00 | Buy | H.C. Wainwright |
7/24/2023 | $43.00 → $45.00 | Buy → Neutral | Goldman |
5/10/2023 | $46.00 | Neutral → Overweight | Piper Sandler |
3/27/2023 | $58.00 | Buy | Berenberg |
3/16/2023 | $42.00 | Outperform → Market Perform | SVB Securities |
JP Morgan downgraded Halozyme Therapeutics from Overweight to Neutral and set a new price target of $57.00 from $52.00 previously
Piper Sandler downgraded Halozyme Therapeutics from Overweight to Neutral and set a new price target of $51.00 from $48.00 previously
TD Cowen initiated coverage of Halozyme Therapeutics with a rating of Outperform and set a new price target of $54.00
144 - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.911 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus® SC in Europe and the UK and VYVGART® Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million, Representing YOY Growth of 13% - 22%, Adjusted EBITDA of $555 - $615 million, Representing YOY Growth of 30% - 44% and Non-GAAP Diluted EPS of $3.65 - $4.05, Representing YOY Growth of 32% - 46% SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") t
SAN DIEGO, July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I8719057. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a
Company Granted New European Patent for ENHANZE® Drug Delivery Platform SAN DIEGO, June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. "We are pleased to be able to raise our full year 2024
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with Halozyme's ENHANZE® drug delivery technology for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) as a twice-a-year, approximately 10-minute subcutaneous (SC) injection to be administered by a healthcare practitioner. "We are pleased that the subcutaneous formulation of OCREVUS, OCR
FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs) with Halozyme's ENHANZE® drug delivery technology. Tecentriq Hybreza™ can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq® (atezolizumab). The treatment will be available in the U.S. for all approved adult indications of intravenous Tecentriq®, including certain types of lung, liver, skin an
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.
SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan
Goldman Sachs analyst Graig Suvannavejh maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $44 to $49.
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 10 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 3 1 1 0 0 3M Ago 3 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.69, a high estimate of $71.00, and a low estimate of $50.00. This upward trend is evident, with the
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 price target.